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Management of Hyperbilirubinemia:
Review of the Revised Guidelines
The American Academy of Pediatrics (AAP) pub-
lished a guideline for the management of
hyperbilirubinemia in 1994. An extensive revision of this
clinical practice guideline was recently published, Man-
agement of Hyperbilirubinemia in the Newborn Infant ≥ 35
Weeks of Gestation (Pediatrics. 2004; 114:297-316). http:/
/aappolicy.aappublications.org/cgi/content/full/pe-
diatrics; 114/1/297
Why revise the guidelines?
The primary trigger for revision of the guidelines was
a disturbing increase in the incidence of kernicterus. In
2001, both the CDC and the Joint Commission on Ac-
creditation of Healthcare Organizations (JCAHO) issued
reports warning of kernicterus in previously healthy
newborns.
What is Kernicterus?
Pathologically, kernicterus refers to the yellow stain-
ing and damage of the brainstem nuclei and cerebellum.
Kernicterus is also used to describe the clinical effects
of severe hyperbilirubinemia. These effects are more
precisely described as “bilirubin encephalopathy”.
Acute bilirubin encephalopathy occurs in three phases.
Early phase (reversible): lethargy, hypotonia, poor feed-
ing. Intermediate phase (possibly reversible): moderate
stupor, irritability, hypertonia, fever and high-pitched
cry, alternating with drowsiness and hypotonia. The
hypertonia is classically manifested by backward arch-
ing of the neck (retrocollis) and trunk (opisthotonos).
Advanced phase (probably non-reversible): pronounced
retrocollis-opisthotonos, shrill cry, no feeding, apnea,
fever, deep stupor to coma, seizures, and death.
The chronic form of bilirubin encephalopathy is char-
acterized by athetoid cerebral palsy (often severe),
hearing loss, dental-enamel dysplasia, and paralysis of
upward gaze. These children usually have normal in-
telligence.
History of the Treatment of
Hyperbilirubinemia
In 1945 exchange transfusions were introduced for
the treatment of Rh hemolytic disease. By 1952 the as-
sociation of kernicterus with high bilirubin levels was
established, with a serum bilirubin greater than 20 mg/
dL considered dangerous. Treatment with phototherapy
emerged in 1956 and Rhogam was developed for the
treatment of Rh hemolytic disease by 1964.
Fear of Kernicterus Was Lost
By the mid-1980s to early 90s, the widespread use of
Rhogam and phototherapy had virtually eradicated
kernicterus. A backlash developed against “excessive
and unnecessary treatment of jaundice” and “fear of
bilirubin levels above 20” (termed vigintiphobia). Ker-
nicterus was thought not to occur unless a hemolytic
condition was present.
Other contributing factors during this time included
changes in breastfeeding and the duration of hospital-
ization for newborns. Breastfeeding increased
significantly, without the benefit of optimal lactation
support services. Hospital stays for mothers and new-
borns decreased from four or more days to as short as
24 hours, resulting in discharge before the normal bi-
lirubin peak at ~3-5 days of age.
The Return of Kernicterus
The previously mentioned factors all contributed to a
re-emergence of kernicterus among term and near-term
breastfed infants who had been discharged from the nurs-
ery as healthy newborns. The alerts in 2001 from the CDC
and JCAHO heightened awareness of kernicterus. Par-
ent advocacy groups, most notably “Parents of Infants
and Children with Kernicterus” (www.pickonline.org),
have sought to increase awareness of this problem and
promote universal bilirubin screening. The National
Quality Forum declared kernicterus as one of the “never
events,” the only pediatric condition on this list. The AAP
6responded with the revised practice guideline in July,
2004.
Focus of the Revised Guideline
The overall aim of the guideline is to promote an ap-
proach that will reduce the frequency of severe neonatal
hyperbilirubinemia and bilirubin encephalopathy. An
additional goal was to minimize the risk of unintended
harm such as increased anxiety, decreased breastfeeding,
or unnecessary treatment and cost. It also emphasized
that kernicterus is largely preventable if appropriate
steps are taken.
Summary of AAP Recommendations
The AAP considers the following as the 10 key rec-
ommendations provided by the guideline. Clinicians
should:
1. Promote and support successful breastfeeding.
2. Establish nursery protocols for the identification
and evaluation of hyperbilirubinemia.
3. Measure the total serum bilirubin (TSB) or trans-
cutaneous bilirubin (TcB) level on infants jaun-
diced in the first 24 hours.
4. Recognize that visual estimation of the degree of
jaundice can lead to errors, particularly in darkly
pigmented infants.
5. Interpret all bilirubin levels according to the
infant’s age in hours.
6. Recognize that infants at less than 38 weeks’
gestation, particularly those who are breastfed, are
at higher risk of developing hyperbilirubinemia
and require closer surveillance and monitoring.
7. Perform a systematic assessment on all infants
before discharge for the risk of severe hyperbiliru-
binemia.
8. Provide parents with written and verbal informa-
tion about newborn jaundice.
9. Provide appropriate follow-up based on the time
of discharge and the risk assessment.
10. Treat newborns, when indicated, with photo-
therapy or exchange transfusion.
Breastfeeding
Clinicians should advise mothers to nurse their in-
fants at least 8 to 12 times per day for the first several
days. The AAP recommends against routine supplemen-
tation of non-dehydrated breastfed infants with water
or dextrose water.
Blood Typing
All pregnant women should be tested for ABO and
Rh (D) blood types and have a serum screen for un-
usual isoimmune antibodies. If a mother has not had
prenatal blood grouping or is Rh-negative, a direct an-
tibody test (Coombs’ test), blood type, and an Rh (D)
type on the infant’s (cord) blood are strongly recom-
mended.
If the maternal blood is group O, Rh-positive, it is an
option to test the cord blood for the infant’s blood type
and direct antibody test, but it is not required provided
that there is appropriate surveillance, risk assessment
before discharge, and follow-up.
Clinical Assessment
Clinicians should ensure that all infants are routinely
monitored for the development of jaundice, and nurs-
eries should have established protocols for the
assessment of jaundice. Jaundice should be assessed
whenever the infant’s vital signs are measured but no
less than every 8 to 12 hours. Protocols should include
the circumstances in which nursing staff can routinely
obtain a transcutaneous bilirubin (TcB) level or order a
total serum bilirubin (TSB) measurement. Visual esti-
mation of the bilirubin level from the degree of jaundice
should be recognized as unreliable, especially in darkly
pigmented infants.
Laboratory Evaluation
A TcB and/or TSB measurement should be performed
on every infant who is jaundiced in the first 24 hours
after birth. The need for and timing of a repeat TcB or
TSB measurement will depend on the zone in which
the TSB falls, the age of the infant, and the evolution of
the hyperbilirubinemia. All bilirubin levels should be
interpreted according to the infant’s age in hours.
Causes of Jaundice
The possible cause of jaundice should be sought in
an infant receiving treatment or whose TSB is rising rap-
idly without obvious explanation. Measurement of
glucose-6-phosphate dehydrogenase (G6PD) level is
recommended in infants receiving phototherapy whose
family history, ethnic background or geographic origins
suggest a risk of G6PD deficiency. It should also be con-
sidered in any infant with a poor response to
phototherapy. G6PD deficiency has been reported to
present in one third of infants with kernicterus.
Risk Assessment Before Discharge
Before discharge, every newborn should be assessed
for the risk of developing severe hyperbilirubinemia,
and all nurseries should establish protocols for assess-
ing this risk. Such assessment is particularly important
in infants who are discharged before the age of 72 hours.
The AAP recommends 2 clinical options used indi-
vidually or in combination for the systematic assessment
of risk: predischarge measurement of the bilirubin level
using TSB or TcB and/or assessment of clinical risk fac-
tors. Whether either or both options are used,
appropriate follow-up after discharge is essential.
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Predischarge Assessment for the Risk of Hyperbilirubinemia in 
 Infants >35 wk Gestation (Pediatrics 2004;114:257-313) with permission AAP 
 
                                            
Date Time Age 
(hrs) 
TcB TSB Initials 
      
      
      
      
      
      
      
      
      
      
      
      
TcB-Transcutaneous Bilirubin 
TSB- Total Serum Bilirubin / Direct 
 
 
Risk Factors for Development of Severe Hyperbilirubinemia * 
 
Risk Factors Major Risk ? Minor Risk ? Decreased risk ?
Predischarge TSB or TcB 
(see nomogram above) 
In high risk zone (>95%) 
 
In high intermediate risk zone (>75%) 
 
Low risk zone (<40%) 
 
Visible Jaundice First 24 hrs  Before discharge    
Gestational age 35 –36 wks  37 –38 wk.  >41wk  
Previous sibling Received phototherapy  Jaundiced, no phototherapy    
Blood groups  
Hemolytic disease 
Blood grp. incompatibility with 
+DAT.  Other known hemolytic 
disease (e.g. G6PD deficiency) 
     
Feeding Exclusive breast (?risk if 
poor feeder or ? wt. loss) 
 Breast fed, nursing well  Exclusive formula 
feeding. 
 
Race East Asian  Hispanic (Mexican) ?  African American 
*unless G6PD def. 
~12% are G6PD deficient 
 
Other factors Cephalhematoma or 
significant bruising 
 Macrosomic infant of IDM,  male 
gender, maternal age >25 yr 
 Discharged from 
hospital after 72 hr. 
 
*The more risk factors present, the greater the risk of developing severe hyperbilirubinemia 
 
 
Follow-up should be provided as follows 
Any infant discharged before age 72 hours should be seen 
within 2 days of discharge. 
 
*If an infant is discharged before age 72 hours AND if you plan to follow up in more than 2 days, please document 
your reasons in the chart. 
Bhutani et al, Pediatrics 1999 103:6-14
856877/3-06     Printed by UI Printing Department
Parent Information
Hospitals should provide both written and verbal
information on jaundice to parents prior to discharge.
Examples in English, Spanish, Chinese, and Italian are
available from the AAP at http://www.aap.org/fam-
ily/jaundicefeature.htm
Follow-up
Follow-up should, in general, be scheduled for ap-
proximately 48 hours after discharge. The goal is to have
the infant evaluated during the time period when the
bilirubin level should be at its peak, which is generally
at 3 to 5 days of age. Lack of early post-discharge fol-
low-up has been a common finding in infants with
kernicterus.
Treatment
Treatment thresholds depend on TSB, gestational age,
and risk factors such as hemolytic disease, asphyxia,
G6PD, lethargy, temperature instability, sepsis, acido-
sis, or albumin level < 3 gm/dL.
If a hemolytic process is occurring, intravenous im-
munoglobulin (0.5-1 gram/kg over 2 hours) may be a
valuable supplementary treatment.
Immediate exchange transfusion is recommended in
any infant who demonstrates intermediate or advanced
bilirubin encephalopathy, even if the TSB is falling.
Implementation Strategies
A systematic approach is recommended, including:
1. Establishment of standing protocols for nursery
assessment of jaundice, including testing TcB and
TSB levels without requiring a physician order.
2. Checklists or reminders associated with risk
factors, age at discharge, and laboratory test results
that provide guidance for appropriate follow-up.
3. Explicit educational materials for parents.
Conclusion
Kernicterus is cause of severe brain injury. With the
systematic approach described in these guidelines, em-
phasizing universal assessment of risk factors,
appropriate screening and treatment and timely post-
discharge follow-up, kernicterus should be largely
preventable.
— Dan Ellsbury, MD
Director of Quality Improvement
Pediatrix Medical Group of Iowa
Neonatologist
Children’s Center at Mercy
Des Moines, Iowa
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Infants at lower risk = > 38 wk. and well  
Infants at medium risk= > 38 wk. +risk factors or 35 – 37 
6/7 wk. & well 
Infants at higher risk= 35-37 6/7 wk. + risk factors    
• Guidelines refer to use of intensive photo-
therapy.
• Use total bilirubin. Do not subtract direct
reacting or conjugated bilirubin
• Risk factors*= isoimmune hemolytic disease,
G6PD deficiency, asphyxia, respiratory distress,
significant lethargy, temperature instability,
sepsis, acidosis, or albumin < 3.0 g/dL (if
measured)
• For well infants 35-36 6/7 wk can adjust TSB
levels for intervention around the medium risk
line. It is an option to intervene at lower TSB
levels for infants closer to 35 wks and at higher
TSB levels for those closer to 37 6/7 wks.
• It is an option to provide conventional photo-
therapy in hospital or at home at TSB levels 2-3
mg/dL below those shown but home photo-
therapy should not be used in any infant with
risk factors.
*The risk factors listed above are conditions that might af-
fect the likelihood of brain damage at different bilirubin levels.
These factors increase the risk of brain damage because of
their negative effects on albumin binding of bilirubin, the
integrity of the blood brain barrier, and the susceptibility of
the brain cells to damage by bilirubin.
